Podcasts about Washington School

At a moment when national politics are testing the boundaries of constitutional protections and human dignity, local communities are asking a vital question: What can we do to protect one another? Town Hall Seattle and The Stranger present the March 19 edition of the Speaking of Seattle civic conversation series, an evening focused on immigrant rights, community responsibility, and the everyday actions that help safeguard our neighbors. This timely conversation explores how federal immigration enforcement policies ripple through local communities — and how ordinary people can respond with care, courage, and solidarity. Together, we examine what it means to treat immigrant rights as human rights, and how community members can act lawfully, safely, and effectively when confronted with fear-based tactics and unconstitutional overreach. Host Marcus Harrison Green is the publisher of Hinton Publishing, the founder of the South Seattle Emerald, and a columnist with The Stranger. Growing up in South Seattle, he experienced first-hand the impact of one-dimensional stories on marginalized communities, which taught him the value of authentic narratives. After an unfulfilling stint in the investment world during his twenties, Marcus returned to his community with a newfound purpose of telling stories with nuance, complexity, and multidimensionality with the hope of advancing social change. This led him to become a writer and found the South Seattle Emerald. An award-winning journalist, he was awarded the Seattle Human Rights Commissions' Individual Human Rights Leader Award for 2020 and named the inaugural James Baldwin Fellow by the Northwest African American Museum in 2022. Panelists Angelina Snodgrass Godoy is Helen H. Jackson Endowed Chair in Human Rights and Director at the Center for Human Rights at the University of Washington. She is Associate Professor of International Studies at the Henry M. Jackson School, Associate Professor of Law, Societies, and Justice, and Adjunct Associate Professor of Sociology. A sociologist by training, her research focuses on human rights in Central and Latin America. Godoy teaches undergraduate and graduate courses in human rights in both the Law, Societies, and Justice program and in the Jackson School of International Studies. Roxana Norouzi is a longtime immigrant rights leader with 20 years of experience in organizing, advocacy, and social justice work with immigrant and refugee communities. She currently serves as Executive Director of OneAmerica, where she first began as an organizing intern 12 years ago and later led education policy efforts that won major state and local victories and secured millions in funding for multilingual education. Over the past decade, she has helped guide OneAmerica through a transformational shift toward deeper grassroots organizing, strategic policy campaigns, and building political power. Roxana is also a clinical instructor at the University of Washington School of Public Health. She earned her MSW from UW and was awarded the Bonderman Fellowship, which took her to 20 countries to study post-conflict regions, migration, and identity. As a first-generation American, her work is grounded in a deep commitment to racial equity and immigrant justice. Erika Evans is the first African American and first person of color to serve as Seattle City Attorney. A graduate of the University of Washington and Seattle University School of Law, Erika began her career in the Seattle City Attorney's Office before serving as an Assistant United States Attorney in the Department of Justice's Terrorism and Violent Crimes Unit and as Civil Rights Coordinator until March 2025, when she resigned following federal policy changes she opposed. She has also served as a pro tem municipal court judge in three Washington jurisdictions. Erika is a past president of the Loren Miller Bar Association and co-chair of the Washington Leadership Institute. Seattle City Councilmember Alexis Mercedes Rinck is known for bringing people together around practical solutions and delivering results. A graduate of Syracuse University and the University of Washington's Evans School of Public Policy and Governance, Rinck built her career as a community organizer and policy leader. She has advanced campaign finance reform, supported public health and human services policy across 38 cities during COVID-19, and held leadership roles at the Sound Cities Association and the King County Regional Homelessness Authority. As a councilmember, she created a dedicated Committee on Federal Policy Changes to respond to federal threats to Seattle and has championed union-built social housing, immigrant rights, and progressive revenue solutions. Presented by Town Hall Seattle and The Stranger.

 When should families start preparing for school registration in Washington? Because enrollment timelines, transfer windows, and kindergarten options vary by district, parents should check local requirements early and gather important documents ahead of time. Special protections help ensure foster youth, homeless students, and military families can enroll without unnecessary delays, making proactive communication with district offices the key to a smooth start. 

In this episode of the Neuroveda Podcast for Complex Health, Gillian Ehrlich sits down with returning guest Dr. Dawn Ibsen, compounding pharmacist and passionate advocate for personalized medicine. Together they unpack the science, history, and growing interest around methylene blue — from its origins as a treatment for malaria to its modern use in brain health, mitochondrial support, longevity, and biohacking.They also dive into the rapidly changing world of compounding pharmacies, including concerns surrounding compounded thyroid medications, the evolving landscape of peptide access, and the balance between innovation, safety, and patient care. This conversation explores what happens when cutting-edge medicine meets regulation and why personalized treatment still matters.Topics include:• Methylene blue safety, dosing, and mechanisms• Mitochondrial health and energy production• Compounding pharmacy quality and patient advocacy• Thyroid medication changes• Peptide regulation and current challenges• The future of personalized medicineBio: Dr. Dawn Ipsen, PharmD, FAPC, FACVP, FACA is a compounding pharmacist with more than 25-years of experience serving human and veterinary patients. She is the owner of two community-based compounding pharmacies in Washington state and is recognized for her expertise in personalized medication therapy, quality compounding practices, and patient-centered care.Dr. Ipsen holds an APC Fellowship and is also a Fellow of the American College of Veterinary Pharmacists and American College of Apothecaries, reflecting her advanced training and leadership in both human and veterinary compounding. In addition, she is a clinical instructor for the University of Washington School of Pharmacy and an affiliate faculty member for Bastyr University. Her professional focus includes women's health, hormone therapy, low-dose naltrexone, dermatology compounding, and complex veterinary medication solutions for small animals, exotic pets, and large animal patients.Dr. Ipsen is deeply engaged in pharmacy advocacy, education, and legislative efforts to protect patient access to compounded medications. She currently holds an APC Board of Directors position and is the founding chair for the WA State Pharmacy Association (WSPA) - Compounding Special Interest Group. The WSPA awarded her with the Distinguished Leadership Award in 2023 and the UW School of Pharmacy Distinguished Alumni Award in 2021. Dr. Ipsen regularly collaborates with prescribers, healthcare professionals, and educators to improve the therapeutic outcomes, health, education and vitality of the communities we serve.

It’s a drug you see doctors on “The Pitt” give patients in the ER for pain relief or sedation. It’s also what cast members on the reality show “The Secret Lives of Mormon Wives” take to connect with their spouses. And it's what some Americans use to treat their depression. Ketamine has gotten negative press in the past few years, like in 2023, when “Friends” co-star Matthew Perry died from “the acute effects of ketamine.” We sat down with a doctor to learn more about this substance that’s showing up more and more in popular culture …and in Seattle, which is home to several ketamine clinics. This is part of our recurring “Ask a Doctor” segment, where we ask medical professionals to help us understand health news and trends. Guest: Dr. Nathan Sackett, an assistant professor in the University of Washington School of Medicine and addiction psychiatrist Related links: She Hoped Ketamine Would Rewire Her Brain. She Didn’t Live to See It Work. | WSJ Center for Novel Therapeutics in Addiction Psychiatry As ketamine clinics emerge in Seattle to treat mental illness, so does debate about safety and regulations | The Seattle Times Ketamine Use on the Rise in U.S. Adults; New Trends Emerge | UC San Diego Today Thank you to the supporters of KUOW, you help make this show possible! Right now, we're asking for listeners to give us a full review of the show. We want to know what you want from the show, so share your thoughts with us at kuow.org/feedback. Also, if you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Ultra-processed foods are everywhere. But we aren’t supposed to eat them. At least, that’s the current discourse around these foods, which can include soda, instant oatmeal and sliced bread. Research has found that diets high in ultra-processed foods are linked to diabetes, obesity, heart disease and many cancers. That's a hard pill to swallow, considering that roughly 70% of our grocery store products are ultra-processed, according to the Yale School of Public Health. So we want a little more clarity on what these foods are, how they could impact us and if it’s really so bad to snack on a granola bar (or order the occasional hot dog at a baseball game). Guest: Dr. Neelendu Dey, a gastroenterologist at the Fred Hutchinson Cancer Center and associate professor of gastroenterology at the University of Washington School of Medicine. Related links: Ultra-Processed Foods Information Sheet | Yale School of Public Health Ultra-processed food: Five things to know | Stanford Medicine News Center What Are Ultra-Processed Foods? | Johns Hopkins | Bloomberg School of Public Health Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Wes Hopkinson, a junior at Washington School for the Deaf in Vancouver, is one of just 64 students nationwide invited to the Deaf Youth Leadership Camp in Stayton, Ore. He's raising $4,500 through GoFundMe to attend the camp, which has built deaf leaders since 1969. https://www.clarkcountytoday.com/people/gofundme-spotlight-vancouver-student-raising-funds-for-prestigious-camp-for-the-deaf/ #DeafYouth #WashingtonSchoolForTheDeaf #DeafLeadership #ClarkCounty #Vancouver #GoFundMe #DeafCommunity #DeafCulture #PacificNorthwest #WashingtonState

Show SummaryOn today's episode, we're replaying a conversation with conversation with playwright and producer Elizabeth Coplan, founder of the Greif Dialogues, a nonprofit theatrical movement that facilitates conversations about dying, death, and grief. We talk about her own connection to service and discuss how Grief Dialogues has developed a specific immersive experience of remembrance and reflection ahead of Memorial DayProvide FeedbackAs a dedicated member of the audience, we would like to hear from you. If you PsychArmor has helped you learn, grow, and support those who've served and those who care for them, we would appreciate hearing your story. Please follow this link to share how PsychArmor has helped you in your service journey Share PsychArmor StoriesAbout Today's GuestElizabeth Coplan is a veteran of marketing and public relations with over four decades of experience. She began her professional journey as an aspiring actor in New York City in 1972 before pivoting to publishing, eventually becoming the managing editor of Chief Executive Magazine. After relocating to California, she climbed the ranks at Collins Foods International, ultimately serving as Director of Corporate Communications.In Seattle, Elizabeth became a trailblazer in professional services marketing, notably serving as the first Northwest marketing director for Touché Ross (now Deloitte). She later became Director of Client Service and Development at Davis Wright Tremaine, where she helped grow the firm from three to ten offices and pioneered strategic sponsorships in the legal sector. After six years, she launched her own consulting firm, advising major clients including Merrill Lynch and the University of Washington School of Law.Her service on nonprofit boards includes the Bainbridge Island Museum of Art and the Intiman Theatre, where she chaired strategic planning. In 2013, after a series of personal losses, Elizabeth began writing to process her grief. This led to the creation of Grief Dialogues, a groundbreaking play and nonprofit initiative that fosters dialogue about death and grief through theatre.Her award-winning works include Hospice: A Love Story, Untold, The Choice, and Honoring Choices, the latter adapted into a film that premiered in Los Angeles and earned multiple festival awards. She also directed and produced Juntos Nos Ayudamos, a film addressing suicide in a Hispanic family, and co-hosts the podcast Out of Grief Comes Art.Elizabeth's writing appears in professional grief therapy publications, and her full-length play 'Til Death premiered Off-Broadway in 2023 with an acclaimed cast. She is currently working on The Book Club, a new play exploring the lives of senior women.Links Mentioned in this Episode Grief Dialogues WebsiteMy Guardian Angel MoviePsychArmor Resource of the WeekThis week's resource of the week is the PsychArmor course, Good Grief. Grief is not only experienced with death, it can also occur with job loss or severe changes to physical well-being. The purpose of this course is to recognize loss and identify what is learned as a result of that loss. You can find the resource here:  https://learn.psycharmor.org/courses/good-grief Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Petros Grivas, MD, PhD Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulating tumor DNA (ctDNA) clearance and clinical outcomes, including event-free and overall survival. Their conversation also highlights the prognostic value of ctDNA and the potential for urinary tumor DNA to more closely correlate with pathologic complete response. Dr. Grivas is a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, as well as the Clinical Research Division at the Fred Hutchinson Cancer Center, where he's also the Medical Director of the International Program and of local and regional outreach.

Support the Northwest Regional SCI System by donating at https://give.uwmedicine.org/sci. After listening, give us your feedback using this quick survey: https://redcap.link/sciforumpod Presented at the SCI Forum September 20, 2023 Chronic pain can be a significant problem for individuals with SCI. It is estimated that 68% of people living with SCI have neuropathic pain and/or musculoskeletal pain. Pain is correlated with a lower quality of life (more depression, sleep disturbance, physical dysfunction, etc.). In this presentation, Charles H. Bombardier, PhD, Rehabilitation Psychologist and Professor in the Department of Rehabilitation Medicine at the University of Washington School of Medicine, will discuss pain and his recent research on delivering remote hypnotic cognitive therapy. He will address what pain is, the biopsychosocial model, why nonpharmacological (non-medication) treatments are needed, and the results of this recent research project to treat pain from a distance. A video of this forum can be found at: https://sci.washington.edu/info/forums/video/remotehypnosis/

Have you ever wondered what really goes on in our country's criminal courts? Many want to believe in the hallowed halls of justice, with ethical and equitable legal processes that pursue truth and enforce the law fairly. But one author argues that this perception hides the reality that the system is broken. Emily Galvin Almanza, also a former public defender, presents her latest work The Price of Mercy: Unfair Trials, a Violent System, and a Public Defender's Search for Justice in America. The text takes us behind closed doors of America's criminal courts, arguing that the institutions that claim to protect us are doing the exact opposite. Examples include data showing that jails actually increase future crime, police corruption in overtime pay, an example of a man incarcerated for decades because scientists mistook dog hair for his own, incentives that push prosecutors to seek convictions, and even how judges may decide cases differently after lunch. Almanza presents examples and offers a blueprint for fixing these issues at their core, and by engaging the general public in helping to shape our collective future. Emily Galvin Almanza is the co-founder and executive director of Partners for Justice, a nonprofit creating a new collaborative model of public defense designed to empower defenders nationwide. Prior to founding PFJ, Emily fought for clients inside the L.A. County Public Defender's Office, the Santa Clara County Public Defender's Office, and the Bronx Defenders, and with the Stanford Three Strikes Project. Her writing has appeared in The Atlantic, The Washington Post, Newsweek, Teen Vogue, and Time, among other publications. Michele E. Storms is the Executive Director of the American Civil Liberties Union of Washington (ACLU of Washington), former Deputy Director of the ACLU of Washington, and previous Assistant Dean for Public Service and executive director of the William H. Gates Public Service Law program at the University of Washington School of Law.  Preceding those roles, she served as a statewide advocacy coordinator first at Columbia Legal Services and later at the Northwest Justice Project. She was also previously on faculty at the University of Washington School of Law where she founded what is now the Child and Youth Advocacy Clinic and taught several other courses.

Your brain is aging faster than it should, and most of the decline is self-inflicted. Neuroscientist Dr. Tommy Wood reveals the exact mechanisms driving cognitive decay, and the biohacking strategies backed by hard science that can stop it, reverse it, and future-proof your brain at any age. -Watch this episode on YouTube: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. Tommy Wood, one of the most credentialed minds working at the intersection of brain optimization, human performance, and longevity. Dr. Wood holds a medical degree from the University of Oxford, a PhD in physiology and neuroscience from the University of Oslo, and serves as Associate Professor of Pediatrics and Neuroscience at the University of Washington School of Medicine. He has published over 100 scientific papers, consulted with Olympians and world champions across more than a dozen sports, and worked directly with Formula 1 drivers to sustain elite focus and reaction time at 200 miles per hour. His forthcoming book, The Stimulated Mind: Future-Proof Your Brain from Dementia and Stay Sharp at Any Age, is the culmination of decades of research and real-world application. Together, Dave and Dr. Wood dismantle the myth that cognitive decline is inevitable, exposing how societal expectations become self-fulfilling prophecies and how the tools of biohacking, including sleep optimization, neuroplasticity training, nootropics, supplements, and strategic exercise, can dramatically shift your brain's long-term trajectory. They dig into the 3S Model of brain health (Stimulus, Supply, Support), the Yerkes-Dodson arousal curve and what it means for focus and flow states, and the surprising truth about AI, boredom, and what actually happens to your brain when you let ChatGPT do your thinking for you. This episode is essential listening for anyone serious about anti-aging, brain optimization, functional medicine, metabolism, human performance, and getting smarter without working harder. You'll Learn: Why cognitive decline is largely a self-fulfilling prophecy driven by expectation, not biology How the 3S Model (Stimulus, Supply, Support) determines your brain's long-term health and resilience What Formula 1 drivers teach us about arousal, flow states, and peak cognitive performance Why high-intensity interval training produces dramatically greater neuroplasticity benefits than Zone 2 cardio alone How creatine, nicotine, nootropics, and other supplements actually affect the aging brain The real data on alcohol, dementia risk, and what "occasional drinking" actually means scientifically How to use AI tools like ChatGPT in a way that builds brain function instead of destroying it Why boredom is a neurological necessity and how chronic low-level stimulation is quietly eroding your cognition What mitochondria and lactate signaling have to do with BDNF and long-term memory How resistance training, coordinative movement, and blood flow restriction each deliver separate and distinct cognitive benefits Thank you to our sponsors! - KILLSwitch | If you're ready for the best sleep of your life, order now at https://www.switchsupplements.com/and use code DAVE for 20% off - Neuronic | Go to www.neuronic.online Code DAVE for $100 off - Danger Coffee | Grab yours at DangerCoffee.comand use code DAVEPOD at checkout for 15% off. - Suppgrade Labs | Grab your DAKE and Minerals 101 duo at shopsuppgradelabs.com and use code DAVEPOD for 15% off today Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Tommy Wood, The Stimulated Mind, brain health, cognitive decline, dementia prevention, neuroplasticity, brain optimization, biohacking, Dave Asprey, human performance, longevity, 3S model, brain stimulation, headroom, cognitive reserve, BDNF, lactate, Zone 2, HIIT, resistance training, blood flow restriction, sleep optimization, nootropics, creatine, nicotine, acetylcholine, supplements, ADHD, arousal curve, flow state, Formula 1, anti-aging, mitochondria, metabolism, AI and the brain, ChatGPT, digital dementia, boredom, neurogenesis, hippocampus, white matter, IGF-1, osteocalcin, alcohol and dementia, TMS, TDCS, vagal nerve stimulation, near infrared light, functional medicine, cognitive stimulation, stereotype embodiment theory Resources: • Learn More About Tommy And His Work At His Website: https://www.drtommywood.com • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 — Trailer 01:28 — Guest Intro: Dr. Tommy Wood 03:37 — F1 Drivers & Arousal Optimization 09:01 — Brain Headroom & the 3S Model 13:14 — Brain Stimulation Tech (TMS, TDCS) 17:50 — Cognitive Decline & Aging 20:55 — Alcohol & Brain Health 24:10 — ADHD & Brain Chemistry 26:53 — Nicotine & Cognitive Enhancement 33:25 — Creatine for the Brain 35:12 — Zone 2 vs. High-Intensity Exercise 39:19 — Strength Training & Brain Benefits 43:12 — Boredom & Cognitive Resilience 45:06 — AI & Brain Health 52:49 — Future-Proofing Your Brain See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sigrid Burruss and Dr. Adrienne Schlatter join Dr. Sandie Morgan to explore what human trafficking actually looks like in healthcare settings, why safety matters more than rushing to the rescue, and how hospitals can build responses that help patients feel seen, supported, and safer -- with a close look at California's new SB 963, requiring emergency departments to screen every patient for trafficking.Chapters(00:00) - Intro + SB 963: The New California Law (03:08) - How Trafficking Survivors Come to Healthcare (05:51) - Recognizing the Signs and Using Screening Tools (10:00) - The Sticker Method: Creative Strategies for Privacy (14:36) - Planting Seeds Instead of Rushing to Rescue (19:27) - Training the Whole Team — Even the Cleaning Staff (24:40) - Where to Find Resources and Training (28:01) - Consent Laws, Reporting, and Adult Patients Dr. Sigrid Burruss & Dr. Adrienne SchlatterDr. Sigrid Burruss is a board-certified surgeon at UCI Health specializing in trauma surgery and surgical critical care. She earned her medical degree from the University of California, San Francisco School of Medicine, completed her general surgery residency at UCLA Medical Center, and a fellowship in surgical critical care at UC San Diego Medical Center. Her professional interests include trauma prevention, reducing trauma recidivism, and understanding the relationship between mental health and physical trauma. She is engaged in connecting patients and families with community support systems to promote long-term recovery, and serves on the Orange County Human Trafficking Task Force Healthcare Subcommittee and CSEC steering committee as a leader in clinical response to child sexual exploitation and human trafficking.Dr. Adrienne Schlatter is a board-certified pediatrician at UCI Health, with dual board certification in Pediatrics and Child Abuse Pediatrics. She earned her medical degree from Rowan University School of Osteopathic Medicine, completed her residency in pediatrics at Los Angeles County USC Medical Center, and a fellowship in child abuse pediatrics at the University of Washington School of Medicine. Her clinical work focuses on the care of children who may be affected by abuse or neglect, including evaluation and coordination within multidisciplinary systems. Dr. Schlatter also serves on the Orange County Human Trafficking Task Force Healthcare Subcommittee and CSEC steering committee, bringing her expertise in child abuse pediatrics to the intersection of clinical care, consent law, and trauma-informed practice.Key Points• SB 963, effective January 1, 2025, requires all California emergency departments to screen every patient for human trafficking and adopt formal policies for doing so -- regardless of whether risk factors are present.• Trafficking survivors may come to the ED for reasons that appear unrelated to trafficking: physical assault with an inconsistent history, recurrent STIs, or chronic conditions like hypertension and diabetes that go unmanaged because the trafficker controls whether they can follow up with a primary care provider.• The triage nurse and check-in staff are often the first point of contact -- not the physician -- making it essential that everyone who encounters a patient, from reception to security to cleaning staff, knows what to look for and how to escalate.• When a potential trafficking survivor arrives with a companion claiming to be a family member, clinical policy and common procedures -- like a separate exam, an X-ray, or a trip to the bathroom for a urine sample -- can create a private moment to ask sensitive questions.• The sticker method gives patients a covert way to signal for help: bathroom posters invite patients to place a sticker on their urine cup if they feel unsafe, prompting staff to create a private conversation even when a trafficker is in the room.• Healthcare providers need to manage the impulse to rescue immediately; many survivors, especially teenagers, may not recognize that they are being trafficked, so the goal is to plant a seed of safety -- not to expect immediate disclosure or departure.• Discharge paperwork can carry covert resources: embedding youth housing, counseling services, and hotline numbers in a generic "age-appropriate resources" sheet means a survivor leaves with something useful even if they are not ready to act on it today.• California consent law gives minors over 12 the right to consent to STI testing, mental health care, and substance use counseling without parental permission -- and anyone can consent to forensic evidence collection after sexual assault -- giving clinicians important tools for trauma-informed care without putting young patients at greater risk.ResourcesSB 963 -- California Hospital Human Trafficking Screening Lawhttps://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240SB963Orange County Human Trafficking Task Force -- Healthcare Subcommitteehttps://www.ochumantrafficking.com/committees/healthcaresubcommitteeQuick Youth Indicators for Trafficking (QYIT)https://resources.rhyttac.org/resources/screening-tool/quick-youth-indicators-trafficking-qyitCSE-IT -- Commercial Sexual Exploitation-Identification Toolhttps://www.westcoastcc.org/cse-it/National Human Trafficking Hotlinehttps://humantraffickinghotline.org/en

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.The video mentioned in this episode that further explains situational tolerance can be found at https://gordie.studenthealth.virginia.edu/learn/alcohol-education/situational-tolerance (created by Dr. Susie Bruce and her team at the Gordie Center).  This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.The video mentioned in this episode that further explains situational tolerance can be found at https://gordie.studenthealth.virginia.edu/learn/alcohol-education/situational-tolerance (created by Dr. Susie Bruce and her team at the Gordie Center). This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

In this series we talk with Dr. Jason Kilmer, professor of psychiatry and behavioral sciences at the University of Washington School of Medicine. He specializes in the development, implementation, and evaluation of substance use prevention and intervention efforts on college campuses and among 18–25 year olds.   While Dr. Kilmer focuses on college campuses, his insights are universal and particularly helpful for parents with teenagers of any age. Share these recordings with your parenting peers as you all navigate this exciting time in human development (ages 14–25) and work to help your kids navigate away from alcohol and other drugs.This podcast is brought to you by the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed here are not necessarily those of SAMHSA or the U.S. Department of Health and Human Services. For questions or comments about this podcast, please contact WhatParentsAreSaying@gmail.com. 

We're creating the normie to trickster pipeline with the help of scholar and game designer, Isaac Sanders! We talk about their work around the archetype of the trickster, not only in folklore and mythology, but in day to day life. Content Warning: This episode contains conversations about or mentions of queerphobia, racism, fascism, and spiders. GuestIsaac Sanders (they/them) is an Afro-Indigenous, non-binary scholar, game designer, and social worker who believes play can change the world — and has the receipts to back it up. A PhD student at the University of Washington School of Social Work, Isaac's research lives at the intersection of AI, youth homelessness, and the radical idea that the systems meant to care for people should actually care for people. They run a transitional age youth program at the Doorway Project, founded Spark Action Lab, design games rooted in lived experience, and create content as @alltimeisaac — bringing social work into the 21st century and building worlds that love us back.Minneapolis SpotlightIf you are a podcaster and want to join us in this effort, please go to bit.ly/mnpodcastads- Café Margeurite - Accepting online gift cards to provide hot drinks and food to staff and community members. Select “Solidarity with Staff & Community” at the bottom of the Order Online page.Housekeeping- Books: Check out our previous book recommendations, guests' books, and more at spiritspodcast.com/books- Call to Action: Send in those urban legend emails!- Submit Your Urban Legends Audio: Call us! 617-420-2344Find Us Online- Website & Transcripts: spiritspodcast.com- Patreon: patreon.com/spiritspodcast- Merch: spiritspodcast.com/merch- Instagram: instagram.com/spiritspodcast- Bluesky: bsky.app/profile/spiritspodcast.com- Twitter: twitter.com/spiritspodcast- Tumblr: spiritspodcast.tumblr.comCast & Crew- Co-Hosts: Julia Schifini and Amanda McLoughlin- Editor: Bren Frederick- Music: Brandon Grugle, based on "Danger Storm" by Kevin MacLeod- Artwork: Allyson Wakeman- Multitude: multitude.productionsAbout UsSpirits is a boozy podcast about mythology, legends, and folklore. Every episode, co-hosts Julia and Amanda mix a drink and discuss a new story or character from a wide range of places, eras, and cultures. Learn brand-new stories and enjoy retellings of your favorite myths, served over ice every week, on Spirits.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast was created in sponsorship with Toyota. Find a vehicle that makes memorable moments happen, from the 2026 RAV4 and Sienna to the Highlander and Grand Highlander. Plan the trip, pack the trunk, gather your crew, and go places—together. Toyota: People are the destination.  “It should be possible to maintain stable cognitive function into your eighth and ninth decades. But we don't really internalize that. We expect decline, and because we expect decline, we're less likely to engage in those things.” Dr. Tommy Wood is a neuroscientist, Associate Professor at the University of Washington School of Medicine, and author of The Stimulated Mind. With degrees from Cambridge and Oxford, he has published more than 100 scientific papers and lectured worldwide on brain health, metabolism, and human performance. He also serves as a performance consultant to world-class athletes, including Olympians and Formula 1 drivers, and co-founded the British Society for Lifestyle Medicine. 00:00 - What we know about brain biomarkers 03:59 - Dementia risk is modifiable 06:29 - Why you should get your steps in 08:52 - The effect of exercise on the hippocampus 15:05 - Muscle is a brain organ 20:42 - Give your brain the fuel it needs 25:12 - Creatine & brain health 27:22 - The convenience crisis 29:54 - The importance of making mistakes 31:30 - How to stimulate your brain enough 33:31 - Social connection = medicine 35:45 - Tommy's dream study 38:12 - The optimization trap Referenced in the episode:  Buy Tommy's book here: https://a.co/d/0aUGHI9s  Find Tommy on his website: https://www.drtommywood.com/  The Pointer Study: https://jamanetwork.com/journals/jama/fullarticle/2837046 The Lancet Study: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/abstract  London Cab Driver Study: https://www.pnas.org/doi/10.1073/pnas.070039597 We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Consumer healthcare is entering a new phase where patients are no longer just looking for convenience. They are looking for affordability, transparency, and provider relationships that actually feel continuous and personalized. In this episode, Dr. Myra Ahmad, CEO of Mochi Health, discusses how her company is building a comprehensive care platform that goes well beyond GLP-1s and weight management. She explains how Mochi combines providers, pharmacies, and software infrastructure in a marketplace model that gives patients more treatment visibility, supports tailored care plans, and expands access to affordable medications with or without insurance. Dr. Ahmad also shares why price transparency matters more than ever as more patients move into high-deductible plans, how operational efficiency and AI can help keep care affordable, and why the next chapter of telehealth will belong to solutions that reduce friction while preserving the provider-patient relationship. Tune in and learn how consumer health platforms can make care more accessible, more transparent, and more aligned with what patients actually want.  About Myra Ahmad: Dr. Myra Ahmad is the CEO of Mochi Health, a telehealth and digital care platform focused on delivering personalized, accessible, and affordable care through certified providers. She earned her MD from the University of Washington School of Medicine and holds a bachelor's degree in biology from Wellesley College. Before leading Mochi Health, Dr. Ahmad built a strong background in research through roles at UCSF, the MIT Koch Institute for Integrative Cancer Research, and the MIT Sloan Fellows Program in Innovation and Global Leadership. Her experience spans clinical research, consumer behavior, and healthcare innovation, giving her a multidimensional perspective on how to expand access while improving the patient experience. Things You'll Learn: Patients increasingly want healthcare solutions that combine affordability, transparency, and continuity instead of forcing them through fragmented experiences. A marketplace model can give providers more flexibility to tailor treatment plans while giving patients more visibility into medication and pharmacy choices. Expanding beyond weight management became a natural step once both providers and patients began looking for broader, ongoing care relationships. Operational efficiency, automation, and AI can help healthcare companies reduce administrative costs without sacrificing access or affordability. The future of telehealth will likely favor solutions that make pricing clear and help patients understand exactly what they are paying for. Resources: Connect with and follow Myra Ahmad on LinkedIn. Follow Mochi Health on LinkedIn and visit their website.

Explore how tax management is evolving through technology and strategic innovation to become a key driver of business efficiency and insight.=====Join Michael Bernard from Vertex as he unpacks the latest SAP Insider Benchmark Research on global tax management, revealing how tax departments navigate a rapidly changing landscape. From complex regulatory environments, such as fragmented e-invoicing standards in Europe, to critical pain points like automating tax control frameworks, this episode offers a rich exploration of what's top of mind for CFOs and CIOs. Learn how granular tax data is becoming a strategic asset for sales and marketing, the growing role of managed services amidst workforce shortages, and why the adoption of AI-driven tax automation is still in early stages despite its promising potential. Michael shares memorable stats, including the impact of retirements on CPA talent pools and strategies companies use to overcome compliance time constraints. Perfect for business leaders seeking practical insights on optimizing ERP environments for tax operations with future-ready technology. Listen, learn, and lead the transformation today.⁠⁠⁠⁠⁠⁠⁠Download Episode Transcript⁠⁠⁠⁠⁠⁠⁠Useful Links: ⁠⁠⁠⁠SAP Cloud ERP⁠⁠⁠⁠Follow Us on Social Media!SAP S/4HANA Cloud ERP: ⁠⁠⁠LinkedIn⁠⁠⁠=====Guest: Michael Bernard, Chief Tax Officer of Transaction Tax at VertexMichael Bernard is the Chief Tax Officer of Transaction Tax. In his role, he provides insight and thought leadership around tax department operations, U.S. indirect tax, tax risk management, and tax policy, as well as emerging tax trends. He is also responsible for influencing emerging technologies which meet the continuing regulatory changes of the corporate tax community. He is an executive-level tax attorney with a diverse portfolio of experience in corporate tax, administration, and finance, including a substantive knowledge of U.S. and international tax laws. Prior to joining Vertex, Michael was in various tax leadership roles at Microsoft Corporation for 28 years, the most recent being General Manager & U.S. Tax Counsel. He led teams in the following functional areas: direct and indirect tax controversy, sales and use, business license, property, tax IT, SOX, and telecommunications. He also co-led a corporate taxpayer advocacy group with the Washington Department of Revenue and was a Director on the Board of the Washington Research Council. He has also testified before administrative and lawmakers at both the federal and state level. Michael earned both a J.D. and a Bachelor of Science in Business Administration from Creighton University. He is a part-time lecturer of Law in the LLM program at the University of Washington School of Law. He also served on the board of directors, executive committee, and chaired committees for The Tax Executives Institute (TEI) for nearly 25 years.Host 1: Richard Howells, SAPRichard Howells has been working in the Supply Chain Management and Manufacturing space for over 30 years. He is responsible for driving the thought leadership and awareness of SAP's ERP, Finance, and Supply Chain solutions and is an active writer, podcaster, and thought leader on the topics of supply chain, Industry 4.0, digitization, and sustainability.Follow Richard Howell on ⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠=====Key Topics: Tax management, ERP, Tax control framework, Automation, Regulatory compliance, Managed services, Workforce skill gap, AI adoption, E-invoicing, Tax analytics

Douglas Opel is a professor in the Department of Pediatrics at the University of Washington School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.J. Opel and S.T. O'Leary. Communicating about Vaccines in a Politically Contentious Climate. N Engl J Med 2026;394:1145-1147.

In episode 189, Jennifer Baybado, a teacher at Sacajawea Elementary in the Vancouver Public School District in the state of Washington, shares her journey working on school food waste solution initiatives.

Full Show Notes: bengreenfieldlife.com/cook2026 In this episode, I welcome regenerative medicine expert Dr Matthew Cook to explore what's new and exciting in regenerative medicine. You'll hear firsthand about groundbreaking stem cell treatments, the best peptide stacks, and how exosomes are shaping the future of health and longevity. Whether you're curious about the science behind anti-aging, optimizing recovery, or what's next for wearable tech and AI in healthcare, this conversation delivers practical insights and actionable takeaways. Dr. Cook graduated from the University of Washington School of Medicine, completed his residency in anesthesiology at the University of California San Francisco (UCSF), and completed fellowships in Anti-Aging, Metabolic and Functional Medicine, and Peptide Therapy with the American Academy of Anti-Aging Medicine. After a decade focused on functional medicine (with 14 years prior working as an anesthesiologist), Dr. Cook's specialty is addressing the most challenging conditions. His proprietary multimodal approach regenerates, repairs, and restores health on a cellular level, dealing with root causes rather than masking symptoms. “Become Boundless” Longevity Retreat | April 29–May 3, 2026 Join Ben Greenfield and Dr. Matthew Cook in Nassau, Bahamas, at Champion Spirit Country Club for the “Become Boundless” Longevity Retreat. This immersive, all-inclusive experience centers on daily workouts and mobility training, advanced longevity and recovery therapies, expert-led workshops and Q&As, guided breathwork and meditation, and organic, nutrient-dense meals. You’ll have hands-on access to leading-edge modalities, including hyperbaric oxygen, cryotherapy, contrast therapy, cold plunges, red light sauna, and performance-focused treatments, all woven into a luxury, ocean-adjacent training environment designed to support deep recovery, resilience, and sustained vitality. Explore details and reserve your spot here. Episode Sponsors: MTE: Boost your wellness on a systemic level with the 13 healthy ingredients of MTE. Check them out at GetMTE.com use code GETMTE for 20% off your first order. Formula IQ: Recuperate IQ by Formula IQ is a comprehensive copper supplement designed to support mitochondrial energy, iron balance, and metabolic health by pairing bioavailable copper with essential cofactors your body needs for proper utilization, which is especially crucial if you've been under chronic stress or supplementing with high-dose zinc. Try it at formulaiq.com and use code BEN for 10% off. BIOptimizers MassZymes: MassZymes is a powerful best-in-class enzyme supplement that improves digestion, reduces gas and bloating, and provides relief from constipation. Go to bioptimizers.com/ben and use code ben15 for 15% off your order. BASED Bodyworks: BASED Bodyworks is a clean, plant-based men's grooming brand offering simple, high-performance essentials from shampoo and skincare to styling, formulated without harsh sulfates or hormone-disrupting chemicals, so you can look and feel your best without compromising your health. Visit basedbodyworks.com and use code BOUNDLESSLIFE for 20% off. Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website).See omnystudio.com/listener for privacy information.

Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "12-Month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent Non-Muscle Invasive Bladder Cancer," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the study's patient-centered approach, eligibility criteria, and quality of life after treatment. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. John Gore, urologist at Fred Hutch Cancer Center and professor of urology at University of Washington School of Medicine. Today, we will be discussing the article titled, "Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer." Thank you for speaking with us, Dr. Gore. Dr. John Gore: Thank you so much for having me. Dr. Davide Soldato: So, I just want to jump right in. We know that patients who are diagnosed with recurrent high-grade non-muscle-invasive bladder cancer can be treated with two different approaches. So, one is radical cystectomy, and the other is bladder-sparing therapy. I just wanted to understand: what was the gap that you were trying to fill with this study? In particular, one point that is very important is that this study is very centered on the preference of the patients. Why did you choose this endpoint instead of going for more solid oncology-based endpoints? Dr. John Gore: Yeah, so CISTO was a study that was derived really organically from patient engagement. I think as a clinical gap in care, making a decision about when to pursue radical cystectomy for patients with non-muscle-invasive bladder cancer is a tough decision for us as clinicians. We did some engagement work partnered with the Bladder Cancer Advocacy Network and my partner Angela Smith, and found that it is also a huge gap for patients. You know, they are very anxious about recurrences, and the decision about when to take out the bladder is a very difficult one. We did an evidence synthesis and found that evidence guiding this decision is fairly limited. The reason we chose more of a patient-reported endpoint is several-fold. One is that we, as part of our engagement work, also worked with our patient survey network to identify outcomes that were important to patients. Some of those are the same outcomes that we care about as clinicians - recurrence-free survival and metastasis-free survival - but several outcomes came out that were more patient-centered. These were patient-reported outcomes such as the burden on my finances, the burden on my caregiver or loved one, and the ability to return to physical activities that are important to them. Part of what is unique about CISTO is that this was a contract with PCORI where we knew we would only have about 12-month outcomes for the majority of our patients. That is too early to really derive a lot of the clinical outcomes, but we are able to answer that patient-centered question of, "Am I going to be able to return to physical activities that are important to me?" And that was the genesis of that as the primary endpoint. Dr. Davide Soldato: So, who were the patients that were eligible to participate in the CISTO trial? What were the key eligibility criteria? This is very particular to this study because this was actually an observational study. Why did you think that such a pragmatic approach still can inform us on what is the best treatment approach for these patients? Dr. John Gore: The intent of CISTO was not necessarily to focus on the tightly defined BCG-unresponsive patient population. That is a clearly important patient population, but every day we are all faced in our real-world practice with patients with challenging, high-grade recurrences that don't fit neatly into that BCG-unresponsive box. The reason we chose a broader inclusion was to help doctors and patients answer these same questions they have when it doesn't fit nicely into this BCG-unresponsive category. You know, maybe their BCG exposure was two years ago, but now they are having a recurrence after intravesical chemotherapy. That is no less challenging a clinical conundrum, and we wanted to be able to enroll those patients. Other key inclusions were that all of the patients in CISTO had to have BCG at some point, and they had to have recent exposure to some adjuvant instillational or intravenous therapy like pembrolizumab. We also had some exclusions that were important. They couldn't be participating in a phase 2 clinical trial, and they couldn't have had a prior upper tract urothelial cancer. The other point about the observational trial design is I think a really important one. Part of our engagement work also asked patients about their willingness to randomize. There is a ton of literature in our history of trials that failed to accrue well when they were comparing a large-scale surgical intervention with a more conservative management strategy. What we found is only about 10% of patients would be willing to randomize when the clinical comparison is between radical cystectomy and bladder-sparing therapy. So it was very clear that an observational study design was the only way we were going to get evidence to inform clinical care when one of the key comparators was radical cystectomy. And so that is why we utilized the observational trial design. Dr. Davide Soldato: Starting to go deeper into the results, you mentioned before that the endpoint you chose for this trial was really centered on what patients thought was more important to them. In particular, the primary endpoint of the study was physical function as measured by the EORTC QLQ-C30 questionnaire. I just wanted to understand: first, did you have a solid hypothesis regarding how physical function could be impacted by either radical cystectomy or bladder-sparing treatments? And second, what were the key results of the study? Dr. John Gore: We figured that at 12 months after enrollment, given the burden and morbidity of a radical cystectomy, that patients in the radical cystectomy arm would have worse self-reported physical functioning than patients in the bladder-sparing therapy arm. We did hypothesize that some of our secondary outcomes might potentially be better after radical cystectomy, such as recurrence-free survival and potentially some other cancer-specific outcomes, because it is a more definitive management strategy. For our primary endpoint, however, we hypothesized that it would be worse. What we found, and the key finding of our study, is that at 12 months after enrollment, physical functioning was not different between patients undergoing radical cystectomy and patients undergoing bladder-sparing therapy, which is just important in terms of clinical counseling because it just means that you can tell your patients, "Gosh, if we could fast-forward your life six to nine months after this procedure, your physical functioning would be similar to as if you had been able to keep your bladder." Dr. Davide Soldato: And you mentioned that there were some key secondary endpoints of the study, which included both other dimensions of quality of life and also hard clinical outcomes. We mentioned metastasis-free survival, for example. Going a little bit into the key secondary quality of life outcomes, we know that radical cystectomy can impact physical functioning, but we also know that bowel, sexual symptoms, and also genitourinary symptoms might potentially be impacted by this type of treatment. We also know that, especially in a system like the US, financial toxicity can be a significant burden for patients. Considering the two different approaches, was radical cystectomy better also in other key secondary quality of life outcomes, and was financial toxicity different between the two arms? Dr. John Gore: Thank you for highlighting some of the really important secondary outcomes that I think are really important to trying to figure out what's best for your patients. Some of the main ones were some of the bladder cancer-specific quality of life outcomes you highlight. Urinary quality of life was worse at enrollment in patients in the radical cystectomy arm but was no different 12 months after. What is unique about how we measure that is we used an instrument called the Bladder Cancer Index because we're comparing a population of patients who have lost their bladder with a population of patients who have retained their bladder, and there are different considerations by gender. And so that instrument is agnostic to urinary diversion status and gender. We found that bowel function and sexual function were worse in the radical cystectomy arm. It appeared that bowel functioning was getting better to the point of near equivalence at 12 months in the radical cystectomy arm but was still inferior to bladder-sparing therapy, and that probably relates to the fact that we use the bowel as part of the urinary diversion, and that causes some transient disruption in bowel function. Financial toxicity is an outcome we weren't initially planning on having as part of the CISTO study, but based on that patient feedback, we made that one of our key secondary outcomes. That actually demonstrated superiority in the radical cystectomy arm. I think it's important that we remember that when we do bladder-sparing therapy, those patients are predisposed to a number of visits to our office, whether they're for instillational therapies or cystoscopy surveillance visits. Sometimes that involves the patient themselves, and sometimes that involves a caregiver. We live in an area with a very large geographic catchment, so sometimes that involves overnight hotel stays and airfare. It can be a particular burden, as you made mention, especially in our healthcare system. Dr. Davide Soldato: Going back to the quality of life dimensions and especially considering the different treatments, 50% of the patients received radical cystectomy with robotic surgery. Did you look a little bit into whether the type of surgery that they received might potentially impact on these dimensions of quality of life? Dr. John Gore: These are some questions that a lot of urologists have asked us in the surgical arm, related to surgical approach, so robotic versus open, and urinary diversion type. We sometimes reconstruct the urinary tract with an incontinent diversion called an ileal conduit where the urine drains tonically into a bag, and we sometimes do a continent diversion where someone typically will have a neobladder, where you reconstruct a sphere reservoir out of intestines and sew it to the urethra. About 20% of patients in the radical cystectomy arm in CISTO had a neobladder. We have not yet looked at specific surgical factors and some of those outcomes. That is one of the secondary analyses that we have planned, but we have not drilled into how different surgical approach factors can affect some of our outcomes. Fortunately, we have about 200 patients in the radical cystectomy arm, so it's enough patients that hopefully we can look at some of those factors in the future. Dr. Davide Soldato: Going back to the clinical endpoints, you mentioned that several of these were measured. There was metastasis-free survival, cancer-specific survival, and progression-free survival. We now have the data at 12 months. I am just wondering if you can comment on those when comparing the radical cystectomy with the bladder-sparing techniques. Dr. John Gore: I think importantly, bladder cancer-specific survival was very high in both arms, over 95% at one year. So both patient populations do very well in terms of cancer-specific and overall survival at one year. You know, when you take out the bladder, you're taking out a big source of recurrences. Not surprisingly, there was a marked reduction in recurrences in the radical cystectomy arm, so they had better recurrence-free survival. There actually was worse progression-free survival in the radical cystectomy arm, but there is a big asterisk to that. As you noted, it is an observational study, and one of the areas of imbalance in the study is that we had higher cancer severity in the radical cystectomy arm. So there was about a 20% rate of progression at the time of radical cystectomy to muscle-invasive and node-positive disease. Of those progressions, the overwhelming majority of them were progressions at the time of radical cystectomy, which I think speaks to a couple of important factors. Number one is the challenge in staging these patients. Our staging of non-muscle-invasive bladder cancer is very reliant on our resection. And so there is this risk of understaging our patients. Number two is just the challenge of decision making, that we fear losing our window of cure in this patient population, which is why we try to steer some patients toward radical cystectomy, and that progression figure kind of speaks to that. Dr. Davide Soldato: Also, one of the factors that was most common in the patients who received radical cystectomy was the presence of other high-risk features. For example, non-urothelial histology, which I think is something that in clinical practice we tend to fear a little bit in terms of recurrence, and so it might potentially bias a little bit towards proposing more strongly radical cystectomy to the patient. Another thing that I wanted to have a comment on, so this is not really in the paper, but I think it speaks a little bit to how the data will evolve over time. Do you imagine these clinical outcomes changing over time, and do you think that with higher maturity of these endpoints, this study might be even more informative when counseling patients regarding what they are obtaining with a radical cystectomy versus the other type of treatments? Dr. John Gore: You know, I think in this cancer universe, 12-month outcomes are great, but I think we all want to see two-year and five-year outcomes. We're very fortunate to supplement the work that we've done in the initial CISTO study, we're very fortunate that we've gotten supplementary funding from the National Cancer Institute to get long-term outcomes in this patient population. So we are continuing to follow all of our CISTO study patients to get two-year and five-year outcomes. What we expect to find is the accrual of new events in the bladder-sparing therapy arm. About 7% of patients in the bladder-sparing therapy arm underwent cystectomy in the first year, but that number will probably go up either as they have recurrences or progression events. We definitely expect the recurrence-free survival to continue to have superiority in the cystectomy arm, but we probably will see the progression events equilibrate as more progression events accrue in the bladder-sparing therapy arm. Maybe by five years, we hypothesize that we'll see clinical superiority in the radical cystectomy arm. By then, we might also see mortality events that separate bladder cancer-specific survival and overall survival between the two arms potentially. But we don't know. Hypothetically, cystectomy has its own downstream risks. It is a major reconstruction with some metabolic sequelae and renal functional sequelae, and so there may be some general medical events that accrue in the cystectomy arm that are also impactful. Dr. Davide Soldato: One other thing that I think should be complimented on this study is that you also looked at several other endpoints that might be important for patients. For example, anxiety symptoms and depression symptoms. Dr. John Gore: Yeah, I think one of the other key secondary outcomes we looked at were mental health outcomes. We utilized the PROMIS domains of anxiety and depression. Not unexpectedly, our radical cystectomy arm patients exhibited higher anxiety symptoms and higher depression symptoms at enrollment. What we found is at 12 months, they actually had significantly lower anxiety and depression than patients in the bladder-sparing therapy arm. We hypothesized in this paper that that actually relates probably mostly to cancer-specific anxiety. You know, when you experience this cavalcade of recurrences, it just breeds an anxiety about adverse cancer-specific outcomes, and by taking out the bladder, you kind of eliminate this prevalent source of anxiety. We followed up the study with a qualitative piece where we interviewed 50 patients and 20 caregivers. Based on those interviews, and that's just a sample of the patient population, it did seem to be cancer-specific anxiety that was driving a lot of those responses. Dr. Davide Soldato: I would like to end with a methodological consideration on your part because we said that this was an observational study. Frequently we tend to think that observational studies come with a lot of bias, and so we tend to downgrade a little bit the results. But I think that a lot of the merit that goes in the CISTO study that was published in the JCO, and I think it also speaks to the fact that this is very high-quality data, comes with the fact that the methodology behind this study was really robust in terms of informing us. Even with this observational study that, as you said, was the only one that we could perform considering the patient population. So just a comment on your part also to speak to the solidity of the data that was published. Dr. John Gore: Importantly, you know, if you look at ClinicalTrials.gov or other sources, CISTO is the only trial that has radical cystectomy as a major comparator. In many ways, this study is our only source of evidence for radical cystectomy. So we'd rather have flawed observational evidence than no evidence at all. We all experience flaws of our RCTs as well. They tend to be these narrowly defined patient populations that may not match the patient in front of you. So I think there are unrecognized flaws on the other side as well. The way that we try to counterbalance that, and none of these techniques are perfect, but we used a strategy called 'targeted maximum likelihood estimation'. Like many methods, such as propensity scores or instrumental variable analysis, what we're trying to do theoretically is coax randomization from non-randomized data. And TMLE, which is the technique we use, tends to be pretty robust to that. So it's the best available way that we can try to counterbalance the bias based on age and clinical severity between the two patient arms. I also think what's important about this is that even when there are biases, I think we are able to infer those out and still extract meaningful details from the data. So even with the biased data, I think we all glean some really important clinical learnings from it. Dr. Davide Soldato: Absolutely, but I would also say that in terms of observational data, the work that you have done is really something that makes us quite confident about what you found in the CISTO study. So with this, I would like to thank you again for joining us today. Dr. John Gore: Thank you so much, and thank you for highlighting the CISTO study. We are very excited about the data. Dr. Davide Soldato: So Dr. Gore, we appreciate you sharing more on your JCO article titled, "Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Guest Disclosure Dr. Gore:Consulting or Advisory Role: Astellas Pharma  

In this episode of Discovery, we speak with Professor Peter Nicolas from the University of Washington School of Law about his new copyright law class, a case study of "The Wizard of Oz." The class debuted in winter quarter and included a mandatory group outing to "The Wiz" musical at Paramount Theatre. Since The Wonderful Wizard of Oz was published in 1900, eventually entering the public domain, each new rendition raises fascinating copyright questions. The 1939 MGM film, "The Wizard of Oz," was separately copyrighted and introduced new expressive elements, along with reinterpretations like "The Wiz," a book and its corresponding Broadway musical which reimagined the story through an African American cultural lens. Nowadays we have spinoffs from the book Wicked which tells the backstory of the Wicked Witch followed by the Broadway musical and now a two-part film adaptation, beginning with "Wicked." Professor Nicolas explains how copyright law goes beyond technical doctrine to be a framework that determines who can tell stories — and how.

It's no secret that large language models and artificial intelligence systems require massive amounts of data, which often runs up against fundamental privacy principles like purpose limitation and data minimization. Privacy and data protection laws - like the EU General Data Protection Regulation - feature concepts like the right to be forgotten and data subject access requests. But these are often in tension with modern AI systems.    Some tools, however, are emerging. One of those methods is "machine unlearning," a suite of approaches to help remedy deletion requests of information that's already been used to train an AI model.    Jevan Hutson, acting assistant professor and director of the Tech-Law Clinic at the University of Washington School of Law, recently co-wrote a law review article on machine unlearning and its implications for privacy law.    In this episode, Hutson explains the concept of machine unlearning and how its suite of techniques can add to the tool belts practitioners and regulators alike. 

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.Episode Breakdown: 1:15 – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers 4:50 – Treatment timing, sequencing, and the rationale for combination strategies 8:00 – Neurology News Minute 10:30 – Clinical trial and real-world implications of dystrophin and CK as biomarkers 16:20 – Anticipated gene therapy innovation and safety considerations heading into 2026 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Send us a textDemand for GLP-1 medications has exploded in recent years. What started as a diabetes treatment has quickly become one of the most talked-about forces in healthcare, reshaping how we think about obesity, metabolic disease, access, affordability, and long-term care.But with rapid growth comes confusion: questions about safety, cost, supply constraints, and whether the current system is actually capable of supporting patients for the long haul.Dr. Myra Ahmad, Founder and CEO of Mochi Health joins CareTalk host David E. Williams to discuss what's getting lost in the GLP-1 conversation, why most care models are not built for long-term obesity treatment, and how Mochi is approaching physician-guided metabolic care at scale.

Seattle's 2021 ordinance decriminalized entheogens — plants and fungi that contain psychoactive indolamines, tryptamines, or phenethylamines—such as psilocybin mushrooms, ayahuasca, mescaline cacti, and iboga. This Salon weaves together two threads: the little-known plant and fungal allies often left off the psychedelic main stage, and the laws that shape how we can (and cannot) work with them today. Legal experts Perry Salzhauer and Daniel Shortt explore what this ordinance means in practice, including how it shapes access, cultivation, and community use of approved entheogenic plants and fungi. Key to this discussion is analyzing the parameters of what decriminalization allows and, more importantly, does not allow. The Salon will cover the interplay between local, state, and federal law and share insights from Perry and Daniel's work in the field. Attendees will gain practical insight into the evolving legal and cultural landscape of entheogens in Seattle and beyond. Perry Salzhauer is a corporate transactions attorney with extensive experience advising businesses in highly regulated and emerging industries, including cannabis and psychedelics. He co-founded Green Light Law Group, a boutique firm focused on cannabis and psychedelics, and has served as both outside and in-house counsel to corporations, investors, and government agencies. His background encompasses securities, environmental compliance, and corporate governance, providing clients with a strategic advantage in navigating complex regulatory frameworks. Daniel Shortt is a regulatory and corporate attorney who advises clients across cannabis, hemp, and psychedelics. His work spans federal agencies, multinational corporations, and entrepreneurial startups, with expertise in transactions, compliance, and regulatory frameworks. A frequent commentator in national outlets like The Washington Post and Bloomberg, Daniel also teaches cannabis law at the University of Washington School of Law. Recognized as a Top 200 Cannabis Lawyer and a Super Lawyers "Rising Star," Daniel bridges legal intricacies with pragmatic business insight in emerging psychedelic markets. __ Psychedelic Salon: Cultivating Conscious Connections Join Seattle-based psychedelics educator and podcast host April Pride in a dynamic series co-produced with Town Hall Seattle. Psychedelic Salon explores the transformative potential of psychedelic medicines through engaging conversations, expert panels, and interactive community discussions. Rooted in scientific evidence, each event highlights unique themes—including grief, seniors, menopause, and more—emphasizing their role in mental health, spiritual growth, and personal optimization. Designed to be inclusive and insightful, this series invites attendees of all backgrounds to discover how psychedelics can foster profound connections, healing, and well-being. About April Pride April Pride is a Seattle-based creative entrepreneur and harm reduction advocate with over two decades of experience building brands at the intersection of lifestyle, cannabis, psychedelics, and women's health. Her work has been featured in The New York Times, Forbes, Vice, and The Guardian. April is the founder of SetSet, the world's first clinician-approved woman-focused platform for safe, accessible psychedelic integration. To learn more, follow April on Substack – aprilpride.substack.com Presented by Town Hall Seattle and SetSet. Events are offered for informational, entertainment, and educational purposes only. Read Town Hall's Program Content Policy.

The federal government wants parents to breastfeed more. In a press conference last month, U.S. Health Secretary Robert F Kennedy Jr. argued that infant formula falls short in comparison to breast milk. And in a strategy report published last September called “Make Our Children Healthy Again," the White House said it would “work to increase breastfeeding rates.” In some corners, these initiatives and comments have ruffled feathers – with critics arguing the emphasis was tantamount to shaming women who can’t or choose not to breastfeed. But they also got us thinking about the science behind the breast milk versus infant formula debate …. and why it’s still so controversial when people have been feeding their babies since, well… forever. Guests: Janelle Guirguis-Blake, a practicing family physician in Tacoma and clinical professor at the University of Washington School of Medicine. Related links: The-MAHA-Strategy-WH.pdf RFK Jr. is investigating infant formula. Here’s what’s at stake | CNN Breastfeeding and Health Outcomes for Infants and Children: A Systematic Review | Pediatrics | American Academy of Pediatrics HHS, FDA Announce Operation Stork Speed to Expand Options for Safe, Reliable, and Nutritious Infant Formula for American Families | FDA Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

In Wards 7 and 8, most students go to public school - but a small number have the opportunity to attend the Washington School for Girls, an independent catholic school that offers full scholarships to its students. This year, with a new campus at the heart of the Southeast community, the girls are looking forward to the start of a new chapter.

Dr. Roy Barsness is the author of the text, Core Competencies in Relational Psychoanalysis: A Guide to Practice, Study and Research (Routledge, 2018) and author of the text: Psychodynamic Supervision: In a New Key (Routledge, 2025). He has published several professional articles, presents frequently at professional conferences and teaches nationally and internationally on relational psychoanalysis. He is the Founder and Executive Director of the Contemporary Psychodynamic Institute, former Professor of Psychology and Academic Dean at The Seattle School of Theology and Psychology and served as the Clinical Director of the Clinical Psychology Program at Seattle Pacific University and Clinical Associate Professor at the University of Washington-School of Medicine. You can find out more by visiting his lecture series at the Contemporary Psychodynamic Institute:    / @contemporarypsycho   or by visiting his website: https://roybarsness.com/ ***The Mind Mate Podcast explores the human condition at the intersection of philosophy and psychotherapy. Hosted by counsellor and psychotherapist Tom Ahern, the podcast engages deeply with questions of meaning, anxiety, freedom, identity, death, love, and what it means to live authentically in the modern world. Find out more here: https://ahern.blog/

Doctors have long recommended regular cervical cancer screenings. Traditionally doctors perform these exams using a speculum, which often say is uncomfortable and, for many, quite painful. Some recent developments could make a large number of these screenings easier. In early January, the Health Resources and Services Administration, which is part of the Department of Health and Human Services, updated its guidelines to say that self-administered tests are an acceptable way to screen for human papillomavirus. HPV is a sexually-transmitted disease that causes the majority of cervical cancer cases. OB-GYNs are hopeful that at-home testing will make cervical cancer screenings easier to access…. and significantly more comfortable. Guests: Dr. Linda Eckert, professor of Obstetrics and Gynecology at the University of Washington School of Medicine Related links: New Guidelines Endorse Self-Swab Alternative to Pap Smear for Cervical Cancer Testing - The New York Times Cervical Cancer Risk Factors | Cervical Cancer | CDC The FDA has approved an at-home HPV test. What you need to know : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

 A recent study from the University of Washington School of Medicine reveals a national snapshot of the ways Americans are vulnerable to financial insecurity after undergoing medical procedures.    Surveys showed that about 38% of people who undergo surgery in the United States report experiencing financial hardship after surgery – meaning they have incurred medical debt and have difficulty paying medical bills, or they delay medical care for fear of cost.    John Scott is a trauma surgeon and researcher who studies health policy at the University of Washington. He joins us to discuss his findings.

Kidney disease often develops quietly and is one of the most serious complications of diabetes. In this episode, we explore why kidney damage is so easy to miss, how early testing can change outcomes, and what actually helps protect kidney health.You'll hear practical, hopeful guidance on food, lifestyle, and everyday choices, plus how to support your kidneys without giving up the flavors and traditions you love.Guest Bio:Dr. Katherine R. Tuttle is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Her collective body of work has shaped the “pillars of therapy“ for diabetes and chronic kidney disease across the spectrum of scientific discovery, clinical trials, and population-level implementation. “Love yourself enough to take care of yourself. You are worth it, and you are salvageable, and we have lots of good treatment options, even in people with advanced kidney disease. I get lots of email and messages from patients who are in advanced stages, and my message to them is, Don't give up.” Question of the Day:How can you make one of your favorite cultural dishes just a little more kidney-friendly—without losing the flavor you love?On This Episode You Will Learn:What diabetic kidney disease is and why it's one of the most serious complications of diabetes, including how it develops and why early detection matters.Early warning signs and progression, plus whether kidney damage can be reversed or if the goal is slowing and protecting kidney function over time.The role of nutrition in kidney health, especially for people with diabetes, and how food choices impact long-term outcomes.Honoring culture and flavor while eating kidney-friendly, with practical ways to adapt traditional dishes without giving them up.Realistic daily steps and community support, including what individuals, healthcare providers, and community programs can do to help prevent kidney disease.Connect with Yumlish!Yumlish Website: YumlishYumlish on Instagram: @yumlish_Yumlish on Facebook: YumlishYumlish on Twitter: @yumlish_Yumlish on LinkedIn: Yumlish Connect with Katherine Tuttle!Twitter(X) URL: @KatherineTuttl8LinkedIn URL: www.linkedin.com/in/katherine-tuttle-390871142 University of Washington School of Medicine Nephrology URL: https://nephrology.uw.edu/ Providence Health Center Website URL: https://www.providence.org/ The National Kidney Foundation: https://www.kidney.org/

This episode is another very personal one. My son eight year old son William was diagnosed with medulloblastoma nearly a year ago. He's since on embarked on an incredible journey of brain surgery, radiation, and chemotherapy – and recently rang the bell completing his treatment right before Thanksgiving.His response to this adversity has been nothing short of amazing and awe-inspiring. His smile and laughter has never ceased, his poise and strength are well-beyond his years, and I've chronicled his story on LinkedIn – where you'll see his incredible strength and optimism on display. Along the way, I've met some incredible people and world changers. One of those world changers is Dr. Jim Olson from Seattle Children's. James M. Olson, MD, PhD, is program director for the Invent at Seattle Children's Postdoctoral Scholars Program, a principal investigator in the Ben Towne Center for Childhood Cancer and Blood Disorders Research, and a professor at the University of Washington School of Medicine. He co-founded three biotechnology companies and has mentored more than 30 graduate students and postdoctoral research fellows. He chaired a national phase III clinical trial for high-risk medulloblastoma patients that led to a 20% improvement in five-year survival for Group 3 patients. Dr. Olson is the principal investigator on multiple projects that focus on developing effective new therapies for pediatric brain tumors; methods that allow surgeons to better visualize the border of brain cancer and normal brain, and the discovery of immunotherapeutics for several cancers. Dr. Olson's game changing research in immunotherapy could potentially revolutionize the standard of care as we know it – and has the potential to replace radiation and chemotherapy. In lab trials, this treatment completely eliminated cancer in 90% of brain tumors that are otherwise universally fatal in children. Mice that received the treatment were alive and disease-free, while the untreated mice died within 18 days.In this podcast, we discuss his research, next steps for funding and clinical trials – and what this could mean for families moving forward. Please enjoy this conversation and donate to Dr. Olson's groundbreaking immunotherapy trial here.

Kristi Henderson invented telehealth at the University of Mississippi Medical Center decades before anyone thought healthcare needed it. While her colleagues were optimizing traditional clinic workflows, Kristi was asking a different question: What if geography didn't dictate healthcare access? By the time the pandemic forced everyone else to figure out virtual care overnight, she'd already spent two decades perfecting it. What makes her approach distinctive isn't just her track record at Amazon, Ascension, and Optum. It's that she worked every level of the healthcare system for 24 years before reaching the C-suite. She understands frontline friction because she lived it. At Amazon, Kristi discovered a framework that changed everything: one-way doors versus two-way doors. Some decisions are irreversible and demand precision. Others are experiments where failure means pivoting fast. That distinction became her playbook for tackling problems most leaders won't touch. But her most counterintuitive move? When she became CEO of Confluent Health, her first hire wasn't a CFO or COO. It was a leader for internal communications. Because brilliant transformation plans fail without deliberate stakeholder engagement. Change happens at the speed of trust. Now Kristi is betting on something that sounds almost naively optimistic: that AI will finally give clinicians their time back by eliminating friction, not replacing human connection. She uses AI daily as her "sidekick" and is building an organization where technology supercharges what only humans can do. Key Takeaways: Why Kristi kept raising her hand for jobs no one else wanted and how taking the hardest assignments became her competitive advantage The Amazon framework that changed everything: one-way doors versus two-way doors, and how to know which type of decision you're making What "change happens at the speed of trust" actually means in practice when you're transforming organizations Kristi's "reverse innovation" approach: why bottoms-up transformation consistently outperforms top-down mandates The counterintuitive first hire Kristi made as CEO, and why communication infrastructure matters more than most leaders realize How to handle naysayers strategically instead of avoiding them or trying to convince them Why Kristi believes the workforce crisis isn't permanent if leaders focus on the right problem The specific ways Kristi uses AI daily as a CEO, and why she sees it as the key to bringing joy back to clinical practice About the Guest Kristi Henderson, DNP, is CEO of Confluent Health, a family of physical therapy and occupational therapy companies. She spent the first 24 years of her career as a practicing nurse practitioner before pioneering telehealth at the University of Mississippi Medical Center, long before the pandemic made it mainstream. Kristi has since led digital transformation at Ascension Health, built clinical operations for Amazon Care, and served as CEO of Optum Everycare. She's Board Chair of the American Telemedicine Association and affiliate faculty at Dell Medical School and the University of Washington School of Nursing. Her career has been defined by raising her hand for challenges others declined and building tech-enabled care models that improve outcomes while reducing clinician burden. Chapters 00:00 - Introduction at Confluent Health 01:57 - From Bedside to Boardroom: The Leadership Journey 06:10 - Amazon Care Lessons: One-Way vs Two-Way Doors 11:07 - Change Happens at the Speed of Trust 14:11 - Overcoming Naysayers: The Early Days of Telehealth 19:11 - Bringing Joy Back to Medicine 22:56 - AI Hacks and Daily Innovation Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Kristi Henderson on LinkedIn Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify

Having a mental health condition, including depression or substance use disorder, does not automatically mean that a physician, nurse or other healthcare professional is unable to provide patient care in a competent, ethical and professional manner. Chris Bundy, MD, MPH, FAPA, FASAM, and other leaders of state-based professional health programs (PHPs) support physicians and other healthcare professionals as they navigate mental health conditions and help find supportive paths back to practice once their illness is managed. In this episode of Caring Greatly, Dr. Bundy talks about how PHPs work, his involvement with the Washington PHP and the Federation of State PHP. He shares some common misperceptions about mental health and substance use, and why the stress and trauma-exposure inherent with working in healthcare environments may create unique vulnerabilities for care team members. Dr. Bundy explains some of the challenges and limitations of PHPs, and discusses how many programs have expanded their purview to support a broader group of healthcare professionals beyond physicians. Today, many PHPs offer support to pharmacists, dentists, physicians' assistants and nurses. Dr. Bundy is Executive Medical Director of the Washington Physicians Health Program (WPHP) and Chief Medical Officer of the Federation of State Physician Health Programs (FSPHP). Board-certified in adult and geriatric psychiatry as well as addiction medicine, he holds faculty appointments as a Clinical Professor of Psychiatry at the University of Washington School of Medicine and Clinical Associate Professor at the Washington State University Elson S. Floyd College of Medicine.  Drawing on his extensive experience as a healthcare leader, medical educator and physician in recovery, Dr. Bundy is dedicated to advancing education, advocacy and support for physician health and care team wellbeing. His contributions have been recognized with the President's Unsung Hero Award from the Washington State Medical Association and the Presidential Recognition Award from FSPHP. Dr. Chris Bundy is a leader who cares greatly. The views and opinions expressed in this podcast are those of the speakers and do not necessarily reflect the views or positions of Stryker. The provided resources may contain links to external websites or third-party content. We do not endorse, control or assume any responsibility for the accuracy, relevance, legality or quality of the information found on these external sites.  

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Tom Fleming, PhD, a professor of biostatistics at the University of Washington School of Public Health in Seattle. Drs Camidge and Fleming discussed how Fleming's interest in biostatistics led to a multifaceted career in clinical trial design and analysis. Fleming pursued a PhD in math and statistics and spent his early career learning to bridge quantitative sciences with clinical medicine, working on landmark trials for adjuvant colon cancer and debunking megadoses of Vitamin C as a cancer treatment. A primary focus of Fleming's career was pioneering the use of Data Monitoring Committees (DMCs) in oncology research to safeguard patient interests and trial integrity, later convincing organizations like SWOG to adopt DMCs to prevent premature data releases and biases. He also co-developed the O'Brien-Fleming monitoring boundary, a statistical framework that allows trials to stop early for efficacy only when the signal is undeniably compelling, thereby protecting scientific rigor. After moving to the University of Washington, Fleming expanded his focus into infectious diseases. He led international efforts that revolutionized HIV/AIDS prevention, including demonstrating a reduction in heterosexual transmission of the disease through antiretrovirals and significantly reducing mother-to-child transmission in resource-limited settings. Fleming remains a staunch advocate for confirmatory trials and the use of overall survival as the "gold standard" end point, often expressing skepticism toward surrogate biomarkers like progression-free survival. In the episode, he emphasized that rigorous science is possible even in the most challenging environments, provided there is a commitment to clinical equipoise and high patient retention. Outside of his professional life, Fleming prioritizes family and coaches youth soccer teams, reflecting his belief in the power of collaboration.

What really keeps the brain sharp as we age — and what quietly puts it at risk?In this episode of the Ageless Athlete Podcast, host Kush Khandelwal speaks with Dr. Tommy Wood, neuroscientist, physician, and strength athlete, about the science of cognitive reserve and why long-term brain health depends on challenge, learning, and effort — not comfort or flow.Flow states feel rewarding, but as Dr. Wood explains, they don't create the kind of stimulus the brain needs to adapt over decades. Instead, the brain thrives when it's pushed to learn new skills, navigate uncertainty, and stay engaged through physical movement, mental effort, and diversified identity.This conversation connects neuroscience, exercise science, and psychology in a practical, accessible way — especially for adults who care about aging well, staying mentally sharp, and maintaining performance into midlife and beyond.

We spend about a third of our lives sleeping, so you'd think we'd know more when it comes to understanding what is going on in our bodies and brains when we're doing it. But studying sleep is surprisingly complex and there are a lot of ideas trying to untangle why we need sleep. This episode, host Dr. Samantha Yammine is joined by Dr. Jeffrey Iliff from the University of Washington School of Medicine to talk about how sleep affects our brains. Sam also explores what we can learn about human sleep from animal sleep patterns and a new study that sorts people into five distinct sleep profiles. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Join Elevated GP: www.theelevatedgp.com Net32.com  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram His interdisciplinary approach to dentistry is founded in both empirical research and clinical experience. He attended the University of Washington for both his undergraduate and graduate studies where he received his D.D.S. degree in 1995 and an M.S.D. and certificate in Prosthodontics in 1998. For his entire career, Dr. Kinzer has been committed to furthering the art and science of dental education. His unique ability to impart complex clinical processes in a logical, systematic and clear methodology differentiates him from other Prosthodontists and makes him a highly regarded educator nationally and internationally. He is a full-time teaching faculty at Spear Education in Scottsdale, AZ. where he is also resides as the Faculty Chairman and Director of Curriculum and Campus Education. Dr. Kinzer is an Affiliate Assistant Professor in the Graduate Prosthodontics Department at the University of Washington School of Dentistry and an Adjunct Faculty at Arizona School of Dentistry and Oral Health. Dr. Kinzer is a member of many professional organizations including the American Academy of Restorative Dentistry and the American Academy of Esthetic Dentistry, of which he is currently the sitting President. He serves on the editorial review board for several recognized dental publications and has written numerous articles and chapters for dental publication. He has been honored with the American College of Prosthodontics Achievement Award and in 2018, he received the Saul Schluger Memorial Award for Excellence in Diagnosis and Treatment Planning from the Seattle Study Club. In 2022 he was inducted into the World's Top 100 Doctors as part of the Interdisciplinary Cohort. In his free time, Gregg cherishes spending time his wife Jill and their 6 children. He enjoys anything that he can do outside: golfing, hiking, running, skiing, and biking, in addition to a nice glass of wine.

My conversation with Aaron starts at about 24 minutes after headlines and clips Subscribe and Watch Interviews LIVE : On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. This show is Ad free and fully supported by listeners like you! Please subscribe now for as little as 5$ and gain access to a community of over 750 awesome, curious, kind, funny, brilliant, generous soul Dr. Aaron E. Carroll is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all.  Before joining AcademyHealth, Dr. Carroll was a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University, where he also served as Associate Dean for Research Mentoring and the director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an MD from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. Dr. Carroll's research focused on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. He is the author of The Bad Food Bible and the co-author of three additional books on medical myths. In addition to having been a regular contributor to The New York Times and The Atlantic, he has written for many other major media outlets and is co-Editor-in-Chief at The Incidental Economist, an evidence-based health policy blog. He also has a popular YouTube channel and podcast called Healthcare Triage, where he talks about health research and health policy. Join us Thursday's at 8EST for our Weekly Happy Hour Hangout!  Subscribe and Watch Interviews LIVE    On YOUTUBE.com/StandUpWithPete ON SubstackStandUpWithPete   Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page Gift a Subscription https://www.patreon.com/PeteDominick/gift Send Pete $ Directly on Venmo All things Jon Carroll  Buy Ava's Art